Abstract
Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have